Hogan Lovells advises Fresenius Kabi on the transfer of the Anápolis production site and the logistics operation in Goiânia, Brazil, to EMS

Press releases | 11 April 2025

Led by Frankfurt partner Dr. Torsten Rosenboom, global law firm Hogan Lovells has advised global healthcare company Fresenius Kabi on an agreement to transfer its generic injectables production plant in Anápolis and the logistics operation in Goiânia, both in Goiás Brazil, to EMS, one of the leading pharmaceutical companies in Latin America.

The transaction is still subject to approval by the competent regulatory authorities.

This transaction aligns with Fresenius Kabi's global strategy of optimizing its production network and continuous pursuit of operational efficiency. With nearly 50 years of operation in Brazil, Fresenius Kabi will continue to be present in the country with a robust portfolio in the areas of Biopharma, Nutrition, Pharma, and MedTech, reinforcing its commitment to providing high-quality solutions for the healthcare sector.

Hogan Lovells has advised Fresenius on all legal aspects of the transaction.

Hogan Lovells team for Fresenius Kabi

Dr. Torsten Rosenboom (Partner), Dr. Malte Ingwersen (Counsel), Daniel Martin Schulz (Counsel), Dr. Marius Rothermund (Senior Associate), Joshua Naumann, Leon Hofmann (Associates) (Corporate M/A, Frankfurt/Hamburg);

Arne Thiermann (Partner, Hamburg), Dr. Benjamin Goehl (Senior Associate, Munich) (Life Sciences / Regulatory).

Fresenius Inhouse

Lukas Fleck (Legal M&A; Lead), Dr. Jan Winzen (Legal M&A), Pablo Bassols Baurier, Marco Cruz, Dr. Christoph Lüer (all Legal Kabi).